Journal of Clinical Pediatrics ›› 2023, Vol. 41 ›› Issue (11): 870-874.doi: 10.12372/jcp.2023.22e1144

• Literature Review • Previous Articles     Next Articles

Research Progress of Presepsin in Children with Sepsis

Reviewer: LIU Jing1, YANG Xinli2, SHI Baohai2, Reviser: ZHANG Qingxiu3   

  1. 1. Department of Respiratory Medicine, Children’s Hospital of Soochow Untversity, Suzhou 215003, Jiangsu, China
    2. Department of Pediatric Intensive Care Unit, Tai'an City Central Hospital (The Affiliated Tai'an City Central Hospital of Qingdao University, Taishan Medical and Nursing Center), Tai’an 271000, Shandong, China
    3. Department of Thoracic Surgery, Tai'an City Central Hospital (The Affiliated Tai'an City Central Hospital of Qingdao University, Taishan Medical and Nursing Center), Tai'an 271000, Shandong, China
  • Received:2022-08-22 Online:2023-11-15 Published:2023-11-08

Abstract:

Sepsis, a life-threatening disease, is one of the main causes of morbidity and even death in pediatric patients. Early diagnosis and timely treatment can improve the patient survival rate. The application of blood culture, C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6) in the diagnosis of sepsis is a hot spot of current research, but its specificity and sensitivity are limited, and the detection time is too long. Soluble leukocyte differentiation antigen 14 subtype (sCD14-ST, or Presepsin) is a novel biomarker that not only has high specificity and sensitivity in the early diagnosis of sepsis in children, but also has certain value in evaluating the severity of sepsis, antimicrobial treatment and prognosis, and the detection method is fast and accurate. It has the feasibility of clinical application.This article reviews the evaluation of Presepsin in the diagnosis of sepsis, with a view to conducting more clinical studies to guide its application.

Key words: soluble leukocyte differentiation antigen 14 subtype, sepsis, child